logo

Teva Pharmaceutical Industries Limited (TEVA)



Trade TEVA now with
  Date
  Headline
1/22/2018 8:04:12 AM Teva: Phase III Study On Subcutaneously Administered Reslizumab In Pre-filled Syringe Did Not Meet Primary Endpoint
1/15/2018 8:01:09 AM Teva Says FDA Approves TRISENOX Injection For First Line Treatment Of Acute Promyelocytic Leukemia
1/10/2018 8:52:20 AM Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options For Drug Development Pipeline
1/8/2018 8:02:22 AM Teva Announces Global License Agreement With Alder In Field Of Anti-CGRP-Based Therapy
12/27/2017 9:01:12 AM Teva Announces Exclusive Launch Of Generic Version Of Reyataz (atazanavir) Capsules In The U.S.
12/18/2017 8:03:17 AM Teva Says FDA Accepts BLA For Fremanezumab
12/15/2017 9:01:05 AM Teva Announces Exclusive Launch Of Generic Viread In The U.S.
12/15/2017 6:45:41 AM RBC Capital Markets Is Lowering Teva Pharmaceutical Industries Limited (TEVA) 2019 Rev. Estimate To 18.479 Billion From 21.123 Billion
12/15/2017 6:45:20 AM RBC Capital Markets Is Cutting Teva Pharmaceutical Industries Limited (TEVA) 2018 Rev. Estimate To 19.299 Billion From 21.103 Billion
12/15/2017 6:44:40 AM RBC Capital Markets Is Increasing Teva Pharmaceutical Industries Limited (TEVA) 2019 Estimate To 3.26 From 3.16
12/15/2017 6:44:16 AM RBC Capital Markets Is Raising Teva Pharmaceutical Industries Limited (TEVA) 2018 Estimate To 3.01 From 3.00